Last reviewed · How we verify
oxyquinoline
oxyquinoline is a drug. It is currently in unknown development.
Oxyquinoline is a small molecule with a conjugate base that acts as a chelating agent, used for the quantitative determination of metal ions. It has been studied in various clinical trials for conditions such as eczema, asthma, epilepsy, and seborrheic dermatitis, often in combination with other medications.
At a glance
| Generic name | oxyquinoline |
|---|---|
| Target | 72 kDa type IV collagenase, Methionine aminopeptidase 1, Methionine aminopeptidase 2 |
| Therapeutic area | Other |
| Phase | unknown |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Cellular Distribution of [89Zr]-Oxine-NCR100 Injection in the Treatment of Subjects With Knee Osteoarthritis (Phase 1)
- Imaging Tumor-infiltrating CD8+ T-cells in Non-small Cell Lung Cancer Upon Neo-adjuvant Treatment With Durvalumab (MEDI4736) (Phase 2)
- Retrospective Study to Evaluate the Safety of Sebryl® and / or Sebryl Plus® in the Treatment of Seborrheic Dermatitis and Psoriasis of the Scalp in Routine Medical Practice. (N/A)
- Phase 1 Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (Phase 1)
- Magen Haim Project - Assessing Hand Hygiene Formulas (Phase 4)
- Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. (Phase 1)
- Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study (Phase 2)
- Unicentric Comparing Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol to Betamethasone + Gentamicin + Tolnaftate + Clioquinol in Acute and Sub-acute Dermatitis Eczematous (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxyquinoline CI brief — competitive landscape report
- oxyquinoline updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about oxyquinoline
What is oxyquinoline?
What development phase is oxyquinoline in?
What does oxyquinoline target?
Related
- Target: All drugs targeting 72 kDa type IV collagenase, Methionine aminopeptidase 1, Methionine aminopeptidase 2
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing